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Introduction: Group A β-haemolytic Streptococcus
(GAS), a Gram-positive bacterium, also known as
Streptococcus pyogenes, causes pyoderma,
pharyngitis and invasive disease. Repeated GAS
infections may lead to autoimmune diseases such as
acute post-streptococcal glomerulonephritis, acute
rheumatic fever (ARF) and rheumatic heart disease
(RHD). Invasive GAS (iGAS) disease is an important
cause of mortality and morbidity worldwide. The
burden of GAS infections is, however, unknown in
Africa because of lack of surveillance systems.
Methods and analysis: The African group A
streptococcal infection registry (the AFROStrep study)
is a collaborative multicentre study of clinical,
microbiological, epidemiological and molecular
characteristics for GAS infection in Africa. The
AFROStrep registry comprises two components: (1)
active surveillance of GAS pharyngitis cases from
sentinel primary care centres (non-iGAS) and (2)
passive surveillance of iGAS disease from microbiology
laboratories. Isolates will also be subjected to DNA
isolation to allow for characterisation by molecular
methods and cryopreservation for long-term storage.
The AFROStrep study seeks to collect comprehensive
data on GAS isolates in Africa. The biorepository will
serve as a platform for vaccine development in Africa.
Ethics and dissemination: Ethics approval for the
AFROStrep registry has been obtained from the Human
Research Ethics Committee at the University of Cape
Town (HREC/REF: R006/2015). Each recruiting site will
seek ethics approval from their local ethics’ committee.
All participants will be required to provide consent for
inclusion into the registry as well as for the storage of
isolates and molecular investigations to be conducted
thereon. Strict confidentiality will be applied
throughout. Findings and updates will be disseminated
to collaborators, researchers, health planners and
colleagues through peer-reviewed journal articles,
conference publications and proceedings.
INTRODUCTION
Group A β-haemolytic Streptococcus (GAS), a
Gram-positive bacterium, also known as
Streptococcus pyogenes, causes skin, mucosal, sys-
temic and autoimmune diseases.1 Repeated
pharyngeal and skin infections with GAS may
lead to serious autoimmune diseases such as
acute post-streptococcal glomerulonephritis,
acute rheumatic fever (ARF) and rheumatic
heart disease (RHD).2 3 Invasive GAS (iGAS)
disease is associated with signiﬁcant morbid-
ity and mortality in children and young
adults worldwide.4 Increases in the number
of cases of both invasive and non-invasive
GAS diseases have been observed globally
since the 1980s5 6 possibly due, inter alia, to
the acquisition of multiple virulence determi-
nants giving rise to a single clone,7 subse-
quently prompting many countries to start
active surveillance systems for iGAS to closely
document the epidemiology of the disease.
A patient disease registry is a powerful sur-
veillance tool in epidemiology.8 Guided by
research questions, registries are developed
to serve multiple purposes and provide a
platform to study the natural history of
disease, clinical features, cost-effectiveness of
treatment strategies and care, to assess safety
Strengths and limitations of this study
▪ AFROStrep will provide the first insights into the
epidemiology of Group A β-haemolytic
Streptococcus (GAS) disease in Africa.
▪ Health facilities collaborating in this study have
huge catchment areas; thus, we anticipate large
numbers of enrolment into the registry.
▪ The AFROStrep study is a clinic-based and
laboratory-based registry and will not address
the true burden of disease in the community.
▪ Given the financial constraints facing many
centres in Africa, it is conceivable that specimens
submitted for laboratory evaluation will represent
the more severe cases.
▪ The registry may be rendered incomplete by not
including skin cultures.
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and harm, and to provide measures of improved quality
of care.9 Registries for streptococcal surveillance have
been established in some developed countries—for
example, Canada, England and the USA, where iGAS is
a notiﬁable disease.10–13
In 2004, the Eurosurveillance programme began to
capture comprehensive information on all cases of iGAS
infection in Europe.14 15 This surveillance programme
was successful in tracking trends in iGAS infection, mon-
itoring clusters and outbreaks, and conducting molecu-
lar epidemiological emm sequence typing on all isolates.
In the UK, routine surveillance data indicate a signiﬁ-
cant increase of iGAS isolates from December 2008
(n=143) compared to the same period in 2007 (n=86).16
In Alberta, Canada, surveillance of iGAS infection col-
lects information that informs vaccine development and
contributes to the implementation and evaluation of
new intervention strategies for controlling GAS
disease.13
Currently, there exists no registry for documenting
GAS-related disease in Africa, despite the importance of
GAS infections in this region. Thus, there is limited
information regarding the emm types of GAS in the
African population. In a study conducted in Cape Town
to identify the emm types of GAS causing symptomatic
pharyngeal infections, 26 different emm types were
recovered.17 Of the 26 emm types in the Cape Town col-
lection, 17 (65%) were represented within the 30-valent
M protein-based vaccine under development.18 In Mali,
a collection of 372 pharyngeal GAS isolates from symp-
tomatic children contained 67 different emm types of
which 18 (27%) were represented in the 30-valent
vaccine.19 Given that systematically collected data are
essential for an effective disease-control programme,20
we have established the AFROStrep registry as an essen-
tial ﬁrst step towards understanding the prevalence of
laboratory-conﬁrmed GAS disease in African countries.
Rationale
In a WHO report, GAS was put in the top 10 leading
causes of mortality worldwide, with the majority of
deaths attributed to RHD, a chronic sequel of GAS pha-
ryngitis.21 Prevalence and incidence data on laboratory-
conﬁrmed GAS infection from African countries are
lacking when compared with industrialised nations,22
although a number of studies in Africa have previously
published data on GAS in a number of countries includ-
ing Ethiopia, Mali, Nigeria, Sudan and Tunisia.22–25
The AFROStrep study is a collaborative study that aims
to establish the ﬁrst registry and biorepository of
laboratory-conﬁrmed GAS isolates in Africa, with one of
its main objectives being to collect comprehensive epi-
demiological, clinical, microbiological and molecular
data for GAS infections on the continent. AFROStrep will
serve as a platform for further investigations including
molecular characterisation of isolates in order to con-
tribute to the growing body of knowledge informing
vaccine development.
METHODS AND ANALYSIS
A ﬂow chart of the procedures for the AFROStrep study
is depicted in online supplementary material S1.
Study design
This is a prospective, regional, multicentre, clinic-based
and laboratory-based registry involving centres in Africa,
many of which are part of the Stop Rheumatic Heart
Disease A.S.A.P. Programme26 and related studies such
as the Global Rheumatic Heart Disease Registry (the
REMEDY study).27 AFROStrep seeks to document the
prevalence, incidence, clinical and molecular character-
istics of laboratory-conﬁrmed GAS infection in Africa.
The pilot phase will focus on South African centres in
Cape Town, Pretoria, Polokwane and Durban. iGAS is
deﬁned as GAS isolated in culture from a sterile site
such as blood and cerebrospinal ﬂuid.28 GAS isolated
from a non-sterile site such as the skin and throat is con-
sidered to be non-iGAS.
The registry will comprise two components:
1. Active surveillance of GAS pharyngitis cases from
which GAS has been isolated at clinics and commu-
nity health centres (non-iGAS).
2. Passive surveillance of laboratory data on GAS iso-
lated from patients with invasive streptococcal disease
(iGAS).
Surveillance objectives of the AFROStrep registry
1. To collect demographic and clinical information
from patients with non-invasive and invasive
laboratory-conﬁrmed GAS infection.
2. To determine the molecular epidemiology of non-
invasive and invasive GAS infection.
3. To assess strategies for treatment, control and preven-
tion of GAS infection.
4. To conduct studies that contribute to the develop-
ment of appropriate intervention such as a vaccine.
Study eligibility
All patients presenting with a sore throat (including ton-
sillitis) at participating clinics and community health
centres regardless of age, and who have not had antibio-
tics in the prior 30 days, will be eligible to participate in
the active surveillance arm of AFROStrep.
For the passive surveillance component, all patients,
irrespective of age, conﬁrmed as having invasive GAS
disease are eligible for inclusion.
Inclusion criteria
Inclusion into AFROStrep is subject to anyone presenting
with a sore throat, microbiological laboratory conﬁrm-
ation of GAS, informed consent and the availability of
clinical data.
Exclusion criteria
Patients will be excluded if no informed consent was
obtained.
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Data collection
Active surveillance
Using existing prevalence estimates of around 21% GAS
among patients with sore throat17 with a 95% CI and a
precision level of 5%, a minimum sample size of 246
participants with pharyngitis needs to be enrolled at
each participating site.29 The study nurse in each site
will seek participation in the study among eligible
patients attending healthcare facilities for treatment of
sore throat. Consenting patients will be examined clinic-
ally on a number of symptoms after which a throat swab
will be taken for microbiological culture. A case report
form (see online supplementary material S2) will be
used for recording data. Patient care will remain within
the domain of the attending clinician or nurse.
Antibiotics prescribed will also be documented. Data
entry will take place at each of the participating sites by
a designated data capturer.
Passive surveillance
Eligible patients will be identiﬁed from positive iGAS
cultures isolated from laboratories serving participating
sites. Clinical data will be obtained from hospital folders.
All participating laboratories will use standardised proto-
cols for identifying GAS from clinical specimens. Data
entry will take place at the AFROStrep Cape Town ofﬁce.
Clinical data and accompanying laboratory data will
be entered into the AFROStrep database designed on the
OpenClinica platform V.3.0 (https://www.openclinica.
com). In addition, isolates will be subjected to cryo-
preservation for long-term storage in the AFROStrep
biorepository, housed at the University of Cape Town,
before being subjected to emm typing according to stan-
dardised protocols.30 Material transfer agreements will
be formulated according to the policies of the respective
countries of participating centres.
The institutions inputting data to the registry own
their data. Requests for data sharing will be decided on
by a registry committee, consisting of the principal inves-
tigators from all participating sites, and will be subjected
to satisfactory evidence regarding the intended use of
the data, maintenance of conﬁdentiality and beneﬁt to
the entire community of patients, including the
individual.
Data analysis plan
The information to be collected will include (but not
limited to) date of birth, gender, date and duration of
illness, presenting clinical features and microbiological
ﬁndings. To protect the privacy of patients, a ﬁle will be
created that will have no speciﬁc identiﬁers. Analysis will
be conducted using Stata V.11.2 (StataCorp, College
Station, Texas, USA). Descriptive statistics will be used to
describe the clinical syndromes associated with invasive
and non-iGAS disease by age. The number of positive
samples obtained each month will be analysed to deter-
mine prevalence of GAS among pharyngitis cases
treated at the health facilities. Geographical information
systems technology (ﬂowing out of recent work by our
group)31 will be used to plot the residences of partici-
pants. Emm typing will be reported as previously
described.30
Ethics and dissemination
Each recruiting site will seek ethics approval from their
local ethics committee. Using standardised case report
forms tailored to local requirements, eligible patients
will be informed about the AFROStrep registry, and their
consent to participate will be recorded prior to enrol-
ment. Children aged 8 years and older will also be
requested to provide assent. Reports and publications
emanating from the AFROStrep registry will not include
any information that identiﬁes either the patient them-
selves, their parents or guardians. Participants will be
identiﬁed throughout the study duration by the study
number allocated to them at the time of enrolment. All
data will be stored on a password-protected computer
and handled in the strictest conﬁdence. The establish-
ment of the biorepository will follow prescribed guide-
lines and documentation will be drawn up to afford
maximum protection for the participants, who will be
requested to provide speciﬁc consent for the long-term
storage of their isolates. Findings and updates will be dis-
seminated to collaborators, researchers, health planners
and colleagues through peer-reviewed journal articles,
conference publications and proceedings.
Status of the study and sites participation
The active and passive surveillance arms of AFROStrep
will commence in February 2016; initially, pilot sites in
South Africa will participate in the AFROStrep registry,
after which, enrolment will involve centres from the rest
of Africa. All participating sites will enrol patients for a
minimum of 2 years. The participating regions in Africa
are shown in ﬁgure 1. A similar study has already been
conducted in Cape Town.17
DISCUSSION
To the best of our knowledge, the AFROStrep study is the
ﬁrst prospective study of clinical, epidemiological and
microbiological characteristics of group A streptococcal
disease in Africa. Our registry, which includes the docu-
menting of non-invasive GAS such as pharyngitis, repre-
sents an improvement on current registries limited to
iGAS information. We will collect detailed data on clin-
ical features at the time of presentation which will be
stored together with corresponding detailed laboratory
information including emm typing proﬁles of GAS
strains. This will contribute to an understanding of
potential vaccine coverage in different geographic
regions, especially those with high rates of ARF/RHD,
which require a detailed understanding of the molecular
epidemiology of GAS infections and the prevalent emm
types circulating in the community.32 Also, the
AFROStrep study will document current practices in
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treating group A streptococcal infection, with particular
reference to prescription of penicillin antibiotics. Finally,
AFROStrep, because of its multicentre nature, presents
the scope for examining regional similarities and differ-
ences in clinical and molecular features and outcomes
of GAS infection.
Strengths and limitations
Health facilities collaborating in this study have huge
catchment areas; thus, we anticipate large numbers of
enrolment which will provide an acceptable population
from which to draw conclusions on the general and
molecular epidemiology of GAS in patients. However,
the AFROStrep study is a clinic-based and laboratory-
based registry and will not address the true burden of
disease in the community. Furthermore, concerning the
passive surveillance component, given the ﬁnancial con-
straints facing many centres in Africa, it is conceivable
that specimens submitted for laboratory evaluation will
represent the more severe cases. Finally, in the light of
the hypothesis that GAS impetigo plays a role in the
pathogenesis of post-streptococcal diseases,33 we acknow-
ledge that the registry may be rendered incomplete by
not including skin cultures, for reasons of the risk of
mixed infections. But, given that many cases of iGAS
begin on the skin, the molecular epidemiology of the
most pathogenic GAS should be captured. In addition,
the physical examination will include notation of coexist-
ent pyoderma. Nevertheless, despite the limitations,
AFROStrep will provide the ﬁrst insights into the epi-
demiology of laboratory-conﬁrmed GAS disease in
African countries.
Summary
Group A streptococcal infection and its complications
continue to be widely prevalent in the world. The over-
whelming burden of GAS-related diseases conﬁrms the
need for improved and effective monitoring and control
strategies. The AFROStrep study represents the ﬁrst
attempt to collect contemporary and comprehensive
data on laboratory-conﬁrmed GAS disease in Africa. The
AFROStrep study will help quantify the burden of GAS
infection, document the prevalent strains presenting in
the respective communities and provide information
that could inform the development of locally sensitive
guidelines, future research programmes and policy
development, all of which have the potential to improve
the management of individuals with GAS infection and
GAS-related diseases.
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Correction
Barth DD, Engel ME, Whitelaw A, et al. Rationale and design of the African group
A streptococcal infection registry: the AFROStrep study. BMJ Open 2016;6:e010248.
The ﬁrst and last names of the fourth author were inadvertently transposed.
‘Alemseged’ is the author’s ﬁrst name and ‘Abdissa’ is the last name.
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